Harnessing The Power Of Cell And Gene Therapy In Oncology

The global cell and gene therapy market is predicted to be worth over $81 billion by 2029, with oncology accounting for 44% of the total market. Advances in oncology, specifically in CAR T-cell therapies and tumor-infiltrating lymphocytes (TILs), are leading the way in cell and gene therapy. However, high treatment costs and complex regulations present challenges. Potential solutions include small-batch manufacturing and automation to reduce costs and increase efficiency. The use of artificial intelligence (AI) in oncology is also being explored, particularly in analyzing deep sequencing data from tumors, which could influence the evolution of cell and gene therapy. However, AI's effectiveness is currently limited by the amount of data available and it is not expected to impact processes requiring direct scientist involvement.